Citations (17)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Anil Wagh, Hangtian Song, Ming Zeng, Li Tao & Tapan K. Das. (2018) Challenges and new frontiers in analytical characterization of antibody-drug conjugates. mAbs 10:2, pages 222-243.
Read now
Read now
Anna Wolska-Washer, Pawel Robak, Piotr Smolewski & Tadeusz Robak. (2017) Emerging antibody-drug conjugates for treating lymphoid malignancies. Expert Opinion on Emerging Drugs 22:3, pages 259-273.
Read now
Read now
Runzhe Chen & Baoan Chen. (2015) Brentuximab vedotin for relapsed or refractory Hodgkin’s lymphoma. Drug Design, Development and Therapy 9, pages 1729-1733.
Read now
Read now
Articles from other publishers (14)
A. J. N. Raymakers, S. Costa, D. Cameron & D. A. Regier. (2020) Cost-effectiveness of brentuximab vedotin in advanced stage Hodgkin’s lymphoma: a probabilistic analysis. BMC Cancer 20:1.
Crossref
Crossref
Osamu Suzuki. (2019) Glycosylation in lymphoma: Biology and glycotherapy. Pathology International 69:8, pages 441-449.
Crossref
Crossref
Natalia Buchely, Rami N. Al-Rohil, Phyu P. Aung, George Jour, Carlos Torres-Cabala, Victor G. Prieto & Doina Ivan. (2018) Dermal xanthomatous infiltrates after brentuximab vedotin therapy in mycosis fungoides with large-cell transformation: A novel histologic finding. Journal of Cutaneous Pathology 45:9, pages 711-715.
Crossref
Crossref
Wendy K. Nevala, John T. Butterfield, Shari L. Sutor, Daniel J. Knauer & Svetomir N. Markovic. (2017) Antibody-targeted paclitaxel loaded nanoparticles for the treatment of CD20+ B-cell lymphoma. Scientific Reports 7:1.
Crossref
Crossref
H. Miles Prince. (2015) CD30 As a Target for the Treatment of Cutaneous T-Cell Lymphoma. Journal of Clinical Oncology 33:32, pages 3691-3696.
Crossref
Crossref
Michael J. Stephenson, Lesley A. Howell, Maria A. O’Connell, Keith R. Fox, Claire Adcock, Jenny Kingston, Helen Sheldrake, Klaus Pors, Stephen P. Collingwood & Mark Searcey. (2015) Solid-Phase Synthesis of Duocarmycin Analogues and the Effect of C-Terminal Substitution on Biological Activity. The Journal of Organic Chemistry 80:19, pages 9454-9467.
Crossref
Crossref
Rajiv S. Magge & Lisa M. DeAngelis. (2015) The double-edged sword: Neurotoxicity of chemotherapy. Blood Reviews 29:2, pages 93-100.
Crossref
Crossref
P. Nijeboer, G. Malamut, C.J. Mulder, N. Cerf-Bensussan, D. Sibon, G. Bouma, C. Cellier, O. Hermine & O. Visser. (2015) Enteropathy-Associated T-Cell Lymphoma: Improving Treatment Strategies. Digestive Diseases 33:2, pages 231-235.
Crossref
Crossref
Tadeusz Robak & Pawel Robak. 2015. Resistance to Immunotoxins in Cancer Therapy. Resistance to Immunotoxins in Cancer Therapy
89
128
.
Soodabeh SaeidniaSoodabeh Saeidnia. 2015. New Approaches to Natural Anticancer Drugs. New Approaches to Natural Anticancer Drugs
33
50
.
Jessica J. Huck, Mengkun Zhang, Jerome Mettetal, Arijit Chakravarty, Karthik Venkatakrishnan, Xiaofei Zhou, Rob Kleinfield, Marc L. Hyer, Karuppiah Kannan, Vaishali Shinde, Andy Dorner, Mark G. Manfredi, Wen Chyi Shyu & Jeffrey A. Ecsedy. (2014) Translational Exposure–Efficacy Modeling to Optimize the Dose and Schedule of Taxanes Combined with the Investigational Aurora A Kinase Inhibitor MLN8237 (Alisertib). Molecular Cancer Therapeutics 13:9, pages 2170-2183.
Crossref
Crossref
Sara Rosati, Yang Yang, Arjan Barendregt & Albert J R Heck. (2014) Detailed mass analysis of structural heterogeneity in monoclonal antibodies using native mass spectrometry. Nature Protocols 9:4, pages 967-976.
Crossref
Crossref
Serengulam V. Govindan, Thomas M. Cardillo, Robert M. Sharkey, Fatma Tat, David V. Gold & David M. Goldenberg. (2013) Milatuzumab–SN-38 Conjugates for the Treatment of CD74+ Cancers. Molecular Cancer Therapeutics 12:6, pages 968-978.
Crossref
Crossref
Ka-To Shum, Jiehua Zhou & John J. Rossi. (2013) Nucleic Acid Aptamers as Potential Therapeutic and Diagnostic Agents for Lymphoma. Journal of Cancer Therapy 04:04, pages 872-890.
Crossref
Crossref